<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35702321</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2211-3835</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta pharmaceutica Sinica. B</Title><ISOAbbreviation>Acta Pharm Sin B</ISOAbbreviation></Journal><ArticleTitle>Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease.</ArticleTitle><Pagination><StartPage>3924</StartPage><EndPage>3933</EndPage><MedlinePgn>3924-3933</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apsb.2022.06.002</ELocationID><Abstract><AbstractText>RNA viruses are critically dependent upon virally encoded proteases to cleave the viral polyproteins into functional proteins. Many of these proteases exhibit a similar fold and contain an essential catalytic cysteine, offering the opportunity to inhibit these enzymes with electrophilic small molecules. Here we describe the successful application of quantitative irreversible tethering (qIT) to identify acrylamide fragments that target the active site cysteine of the 3C protease (3C<sup>pro</sup>) of Enterovirus 71, the causative agent of hand, foot and mouth disease in humans, altering the substrate binding region. Further, we re-purpose these hits towards the main protease (M<sup>pro</sup>) of SARS-CoV-2 which shares the 3C-like fold and a similar active site. The hit fragments covalently link to the catalytic cysteine of M<sup>pro</sup> to inhibit its activity. We demonstrate that targeting the active site cysteine of M<sup>pro</sup> can have profound allosteric effects, distorting secondary structures to disrupt the active dimeric unit.</AbstractText><CopyrightInformation>&#xa9; 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100076, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craven</LastName><ForeName>Gregory B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Pengjiao</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100076, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesti</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London W12 0BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xinran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London W12 0BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Child</LastName><ForeName>Emma S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Rhodri M L</ForeName><Initials>RML</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Wenchao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London W12 0BZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Life Sciences, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100076, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Acta Pharm Sin B</MedlineTA><NlmUniqueID>101600560</NlmUniqueID><ISSNLinking>2211-3835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allosteric inhibition</Keyword><Keyword MajorTopicYN="N">Covalent fragments</Keyword><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">Protease inhibitors</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>2</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35702321</ArticleId><ArticleId IdType="pmc">PMC9181371</ArticleId><ArticleId IdType="doi">10.1016/j.apsb.2022.06.002</ArticleId><ArticleId IdType="pii">S2211-3835(22)00268-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poltronieri P., Sun B., Mallardo M. RNA Viruses: RNA roles in pathogenesis, coreplication and viral load. Curr Genom. 2015;16:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763971</ArticleId><ArticleId IdType="pubmed">27047253</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolhouse M.E.J., Brierley L. Epidemiological characteristics of human-infective RNA viruses. Sci Data. 2018;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819479</ArticleId><ArticleId IdType="pubmed">29461515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.Y. Enterovirus 71 infection and neurological complications. Korean J Pediatr. 2016;59:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan L.N.T., Hong N.T.T., Nhu L.N.T., Nguyet L.A., Ny N.T.H., Thanh T.T., et al. Severe enterovirus A71 associated hand, foot and mouth disease, Vietnam, 2018: preliminary report of an impending outbreak. Euro Surveill. 2018;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247458</ArticleId><ArticleId IdType="pubmed">30458911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.Y., Kung Y.A., Shih S.R. Antivirals and vaccines for enterovirus A71. J Biomed Sci. 2019;26:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D., Chen S., Cheng A., Wang M. Roles of the Picornaviral 3C proteinase in the viral life cycle and host cells. Viruses. 2016;8:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810272</ArticleId><ArticleId IdType="pubmed">26999188</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.M., Liang P.H. Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors. Expert Opin Ther Pat. 2010;20:59&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021285</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., et al. In&#xa0;vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43:2444&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47:3907&#x2013;3916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.</Citation></Reference><Reference><Citation>Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C., Stevens R.C., et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci U S A. 2006;103:5717&#x2013;5722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458639</ArticleId><ArticleId IdType="pubmed">16581910</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J., Petter R.C., Baillie T.A., Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">21455239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.S., Rattu M.A., Kim S.S. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract. 2016;22:92&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">25425007</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterworth S., Cross D.A.E., Finlay M.R.V., Ward R.A., Waring M.J. The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M. MedChemComm. 2017;8:820&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6072417</ArticleId><ArticleId IdType="pubmed">30108799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson P.A., Widen J.C., Harki D.A., Brummond K.M. Covalent modifiers: a chemical perspective on the reactivity of &#x3b1;,&#x3b2;-unsaturated carbonyls with thiols via hetero-michael addition reactions. J Med Chem. 2017;60:839&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5308545</ArticleId><ArticleId IdType="pubmed">27996267</ArticleId></ArticleIdList></Reference><Reference><Citation>Douangamath A., Fearon D., Gehrtz P., Krojer T., Lukacik P., Owen C.D., et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11:5047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542442</ArticleId><ArticleId IdType="pubmed">33028810</ArticleId></ArticleIdList></Reference><Reference><Citation>Craven G.B., Affron D.P., Allen C.E., Matthies S., Greener J.G., Morgan R.M.L., et al. High-throughput kinetic analysis for target-directed covalent ligand discovery. Angew Chem Int Ed Engl. 2018;57:5257&#x2013;5261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947712</ArticleId><ArticleId IdType="pubmed">29480525</ArticleId></ArticleIdList></Reference><Reference><Citation>Craven G.B., Affron D.P., K&#xf6;sel T., Wong T.L.M., Jukes Z.H., Liu C.T., et al. Multiparameter kinetic analysis for covalent fragment optimization by using quantitative irreversible tethering (qIT) Chembiochem. 2020;21:3417&#x2013;3422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754465</ArticleId><ArticleId IdType="pubmed">32659037</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham F. Daily briefing: pfizer's COVID pill looks promising. Nature. 08 November 2021 doi: 10.1038/d41586-021-03379-5. Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03379-5</ArticleId><ArticleId IdType="pubmed">34754102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Fang C., Zhang Q., Zhang R., Zhao X., Duan Y., et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2022;13:689&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8533666</ArticleId><ArticleId IdType="pubmed">34687004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.D., Chen G.S., Liu J.R., Hsieh C.E., Chern J.W. Acrylamide functional group incorporation improves drug-like properties: an example with EGFR inhibitors. ACS Med Chem Lett. 2019;10:22&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331160</ArticleId><ArticleId IdType="pubmed">30655941</ArticleId></ArticleIdList></Reference><Reference><Citation>Congreve M., Carr R., Murray C., Jhoti H. A 'rule of three' for fragment-based lead discovery? Drug Discov Today. 2003;8:876&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">14554012</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan M.E., Abramite J.A., Anderson D.P., Aulabaugh A., Dahal U.P., Gilbert A.M., et al. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J Med Chem. 2014;57:10072&#x2013;10079.</Citation><ArticleIdList><ArticleId IdType="pubmed">25375838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Fan T., Yao X., Wu Z., Guo L., Lei X., et al. Crystal structures of&#xa0;enterovirus 71 3C protease complexed with rupintrivir reveal the&#xa0;roles of catalytically important residues. J Virol. 2011;85:10021&#x2013;10030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Zhang B., Jiang X.M., Su H., Li J., Zhao Y., et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R.L., Kania R.S., Brothers M.A., Davies J.F., Ferre R.A., Gajiwala K.S., et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem. 2020;63:12725&#x2013;12747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571312</ArticleId><ArticleId IdType="pubmed">33054210</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinajsti&#x107; N. Calculation of carbon-sulphur bond lengths. Tetrahedron Lett. 1968;9:1529&#x2013;1532.</Citation></Reference><Reference><Citation>Khan A., Heng W., Wang Y., Qiu J., Wei X., Peng S., et al. In silico and&#xa0;in&#xa0;vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro) Phytother Res. 2021;35:2841&#x2013;2845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013176</ArticleId><ArticleId IdType="pubmed">33448101</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Umbreen S., Hameed A., Fatima R., Zahoor U., Babar Z., et al. In silico mutagenesis-based remodelling of SARS-CoV-1 peptide (ATLQAIAS) to inhibit SARS-CoV-2: structural-dynamics and free energy calculations. Interdiscip Sci. 2021;13:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319699</ArticleId><ArticleId IdType="pubmed">34324157</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>